Literature DB >> 16652376

Antitumor activity of an Ets protein, PEA3, in breast cancer cell lines MDA-MB-361DYT2 and BT474M1.

Zhenming Yu1, Weiya Xia, Hong-Ying Wang, Shao-Chun Wang, Yong Pan, Ka Yin Kwong, Gabriel N Hortobagyi, Mien-Chie Hung.   

Abstract

Polyomavirus enhancer activator 3 (PEA3) is a member of the Ets family of transcription factors. We demonstrated in a previous study that, by downregulating the HER-2/neu oncogene at the transcriptional level, PEA3 can inhibit the growth and development into tumors of HER-2/neu-overexpressing ovarian cancer cells. Here, we establish stable clones of the human breast cancer cell line MDA-MB-361DYT2 that express PEA3 under the control of a tetracycline-inducible promoter. Ectopic expression of PEA3 in this cell line inhibited cell growth and resulted in cell cycle accumulation in the G1 phase. We demonstrate that expression of PEA3 in an orthotopic breast cancer model inhibited tumor growth and prolonged the survival of tumor-bearing mice. In a parallel experiment with another breast cancer cell line, BT474M1, we were unable to obtain stable PEA3-inducible transfectants, suggesting that PEA3 may exert a strong growth inhibition effect in this cell line. Indeed, PEA3 coupled with the liposome SN2 demonstrated therapeutic effects in mice bearing tumors induced by BT474M1. These results provide evidence for the antitumor activity of PEA3 in human breast cancers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16652376     DOI: 10.1002/mc.20212

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  18 in total

1.  Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation.

Authors:  Zhengyuan Zhou; Ganesan Vaidyanathan; Darryl McDougald; Choong Mo Kang; Irina Balyasnikova; Nick Devoogdt; Angeline N Ta; Brian R McNaughton; Michael R Zalutsky
Journal:  Mol Imaging Biol       Date:  2017-12       Impact factor: 3.488

Review 2.  Molecular mechanisms of ETS transcription factor-mediated tumorigenesis.

Authors:  Adwitiya Kar; Arthur Gutierrez-Hartmann
Journal:  Crit Rev Biochem Mol Biol       Date:  2013-09-25       Impact factor: 8.250

3.  Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET.

Authors:  Ganesan Vaidyanathan; Darryl McDougald; Jaeyeon Choi; Eftychia Koumarianou; Douglas Weitzel; Takuya Osada; H Kim Lyerly; Michael R Zalutsky
Journal:  J Nucl Med       Date:  2016-02-18       Impact factor: 10.057

4.  131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment.

Authors:  Matthias D'Huyvetter; Jens De Vos; Catarina Xavier; Marek Pruszynski; Yann G J Sterckx; Sam Massa; Geert Raes; Vicky Caveliers; Michael R Zalutsky; Tony Lahoutte; Nick Devoogdt
Journal:  Clin Cancer Res       Date:  2017-07-27       Impact factor: 12.531

5.  Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation.

Authors:  Zhengyuan Zhou; Satish K Chitneni; Nick Devoogdt; Michael R Zalutsky; Ganesan Vaidyanathan
Journal:  Bioorg Med Chem       Date:  2018-03-15       Impact factor: 3.641

6.  Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation.

Authors:  Jaeyeon Choi; Ganesan Vaidyanathan; Eftychia Koumarianou; Choong Mo Kang; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2017-09-19       Impact factor: 2.408

7.  Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling.

Authors:  Marek Pruszynski; Eftychia Koumarianou; Ganesan Vaidyanathan; Hilde Revets; Nick Devoogdt; Tony Lahoutte; H Kim Lyerly; Michael R Zalutsky
Journal:  J Nucl Med       Date:  2014-02-27       Impact factor: 10.057

8.  Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody.

Authors:  Marek Pruszynski; Eftychia Koumarianou; Ganesan Vaidyanathan; Hilde Revets; Nick Devoogdt; Tony Lahoutte; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2012-11-15       Impact factor: 2.408

9.  N-Succinimidyl 3-((4-(4-[(18)F]fluorobutyl)-1H-1,2,3-triazol-1-yl)methyl)-5-(guanidinomethyl)benzoate ([(18)F]SFBTMGMB): a residualizing label for (18)F-labeling of internalizing biomolecules.

Authors:  Ganesan Vaidyanathan; Darryl McDougald; Jaeyeon Choi; Marek Pruszynski; Eftychia Koumarianou; Zhengyuan Zhou; Michael R Zalutsky
Journal:  Org Biomol Chem       Date:  2015-12-08       Impact factor: 3.876

10.  Pea3 transcription factors and wnt1-induced mouse mammary neoplasia.

Authors:  Rebecca Baker; Claire V Kent; Rachel A Silbermann; John A Hassell; Lawrence J T Young; Louise R Howe
Journal:  PLoS One       Date:  2010-01-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.